. 2022 Nov 23;65(23):15789–15804. doi: 10.1021/acs.jmedchem.2c01348

Table 3. Cytotoxic Activity of 3′-dA and Compounds 7a,b, d–f^a.

	HEL92.1.7		NCI-H929		RPMI-8226		Jurkat		Z138		RL		HS445
comp	LC₅₀	MI_%	LC₅₀	MI_%	LC₅₀	MI_%	LC₅₀	MI_%	LC₅₀	MI_%	LC₅₀	MI_%	LC₅₀	MI_%
3′-dA	68.9	88	>198	24	>198	1	>198	20	12.15	95	>198	17	>198	2
7a	8.07	100	6.07	100	14.72	96	1.44	100	26.97	95	3	93	30.53	98
Rp-7a	11.0	98	19.0	97	25.0	90.8	2.82	97	-	-	4.0	96.8	42.0	99
Sp-7a	11.0	100	16.0	94	19.0	86.8	2.29	90	-	-	2.64	92.6	67.0	75
7b	2.94	98	3.38	99	9.48	102	0.9	100	6.32	100	1.68	96	10.18	96
7d	4.23	99	7.21	104	24.06	103	7.15	100	5.65	100	11.61	100	39.53	102
7e	14.49	99	7.57	100	31.05	106	4.75	100	68.18	76	7.26	90	42.73	92
7f	15.42	101	16.11	98	46.7	89	7.01	95	43.84	93	13.54	88	54.98	85
PTX	0.02	83	0.003	82	0.003	91	0.005	97	0.002	99	0.003	83	0.01	74

Cytotoxicity data reported as μM LC₅₀ values (concentration of drug causing 50% cell death) and MI% values (maximum inhibitory effect of the drug at the range of concentrations considered). PTX: paclitaxel (control); (-) not tested.

Table 3. Cytotoxic Activity of 3′-dA and Compounds 7a,b, d–fa.

Table 3. Cytotoxic Activity of 3′-dA and Compounds 7a,b, d–f^a.